Abstract
Methotrexate (MTX) is a folate antagonist widely used both as an anticancer drug and as an immunosupressant. Administration of an 8-day methotrexate and folinic acid regime may be associated with pleuritic chest pain and pneumonitis. We have reviewed the toxicity seen in 168 consecutive patients treated with low-dose MTX for persistent trophoblastic disease. Twenty-five per cent of patients developed serosal symptoms, pleurisy was the commonest complaint. The majority of patients had mild to moderate symptoms which were controlled with simple analgesia and did not necessitate a change in treatment; 11.9% had severe symptoms which necessitated a change in treatment. One patient developed a pericardial effusion and a second patient developed severe reversible peritoneal irritation. The possible aetiology and pathophysiology of methotrexate-induced serosal toxicity is discussed. © 1999 Cancer Research Campaign
Keywords: methotrexate, pericarditis, peritonitis, pleurisy, pneumonitis, serosal complications
Full Text
The Full Text of this article is available as a PDF (56.1 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Akoun G. M., Gauthier-Rahman S., Mayaud C. M., Touboul J. L., Denis M. F. Leukocyte migration inhibition in methotrexate-induced pneumonitis. Evidence for an immunologic cell-mediated mechanism. Chest. 1987 Jan;91(1):96–99. doi: 10.1378/chest.91.1.96. [DOI] [PubMed] [Google Scholar]
- Bagshawe K. D., Dent J., Newlands E. S., Begent R. H., Rustin G. J. The role of low-dose methotrexate and folinic acid in gestational trophoblastic tumours (GTT). Br J Obstet Gynaecol. 1989 Jul;96(7):795–802. doi: 10.1111/j.1471-0528.1989.tb03318.x. [DOI] [PubMed] [Google Scholar]
- Cooper J. A., Jr, White D. A., Matthay R. A. Drug-induced pulmonary disease. Part 1: Cytotoxic drugs. Am Rev Respir Dis. 1986 Feb;133(2):321–340. doi: 10.1164/arrd.1986.133.2.321. [DOI] [PubMed] [Google Scholar]
- Forbat L. N., Hancock B. W., Gershlick A. H. Methotrexate-induced pericarditis and pericardial effusion; first reported case. Postgrad Med J. 1995 Apr;71(834):244–245. doi: 10.1136/pgmj.71.834.244. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gillespie A. M., Lorigan P. C., Radstone C. R., Waterhouse J. C., Coleman R. E., Hancock B. W. Pulmonary function in patients with trophoblastic disease treated with low-dose methotrexate. Br J Cancer. 1997;76(10):1382–1386. doi: 10.1038/bjc.1997.564. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ginsberg S. J., Comis R. L. The pulmonary toxicity of antineoplastic agents. Semin Oncol. 1982 Mar;9(1):34–51. [PubMed] [Google Scholar]
- Massin F., Coudert B., Marot J. P., Foucher P., Camus P., Jeannin L. La pneumopathie du méthotrexate. Rev Mal Respir. 1990;7(1):5–15. [PubMed] [Google Scholar]
- White D. A., Rankin J. A., Stover D. E., Gellene R. A., Gupta S. Methotrexate pneumonitis. Bronchoalveolar lavage findings suggest an immunologic disorder. Am Rev Respir Dis. 1989 Jan;139(1):18–21. doi: 10.1164/ajrccm/139.1.18. [DOI] [PubMed] [Google Scholar]